Labcorp (Laboratory Corp) stock (US53223X1072): National Pension Service buying adds to analyst support

Labcorp shares on the NYSE traded around USD 260 on 06/01/2026 as South Korea’s National Pension Service disclosed a higher stake and analysts maintained a broadly positive view on the United States-based diagnostics group.

Labcorp (Laboratory Corp) started the week with its stock trading near USD 260 on the New York Stock Exchange on 06/01/2026, while new filings showed that South Korea’s National Pension Service increased its position in the United States-based diagnostics and laboratory services group during the fourth quarter, underscoring ongoing institutional interest in the NYSE:LH listing, according to MarketBeat as of 06/01/2026.MarketBeat as of 06/01/2026

The stock traded at USD 260.21 on 06/01/2026 on the NYSE, highlighting a broadly steady performance in the context of recent news flow, including strategic collaborations in genetic testing that aim to widen Labcorp’s role in precision oncology, according to MarketBeat as of 06/01/2026 and Zacks coverage dated 05/31/2026.Zacks as of 05/31/2026

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: LH
• Sector/industry: Diagnostics and laboratory testing services
• Headquarters/country: Burlington, United States
• Core markets: United States with international reference-lab and central-lab services
• Key revenue drivers: Routine and specialty lab testing, oncology and genetic testing, and central laboratory services for drug development
• Home exchange/listing venue: New York Stock Exchange (LH)
• Trading currency: USD

Labcorp (Laboratory Corp): core business model

Labcorp focuses on providing diagnostic testing and drug-development laboratory services, with revenue largely generated from high-volume clinical lab work, specialized genetic and oncology testing, and support services for biopharmaceutical trials.

What banks and research houses say about Labcorp (Laboratory Corp)

According to MarketBeat data cited on 06/01/2026, Labcorp carries a consensus rating of "Moderate Buy" and an average price target of USD 308.00 across the analyst coverage tracked by the platform, signaling that research houses broadly maintain a constructive stance on the NYSE-listed diagnostics stock.MarketBeat as of 06/01/2026

The same MarketBeat snapshot as of 06/01/2026 notes that the stock’s average target of USD 308.00 stands above the USD 260.21 trading level recorded when the NYSE opened on 06/01/2026, indicating that, on average, covering analysts still see further upside potential in Labcorp’s equity valuation relative to current market pricing.MarketBeat as of 06/01/2026

Conclusion

Labcorp’s share price around USD 260 on 06/01/2026, coupled with the disclosed fourth-quarter stake increase by South Korea’s National Pension Service, points to continuing institutional participation in the United States-listed diagnostics name.

Against this backdrop, the "Moderate Buy" consensus and USD 308.00 average price target reported by MarketBeat as of 06/01/2026 underline that the analyst community, on balance, still sees room for value in Labcorp’s equity, even as investors monitor execution in areas such as genetic testing collaborations and broader healthcare demand trends.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.